Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival

Gastroenterology

Volumn 148, Issue 7, 2015, Pages 1371-1382

  Kim, Hyung Don ^a   Lim, Young Suk ^a   Han, Seungbong ^a   An, Jihyun ^a   Kim, Gi Ae ^a   Kim, So Yeon ^a   Lee, So Jung ^a   Won, Hyung Jin ^a   Byun, Jae Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

BCLC; Combined Image Analyses; Gadoxetic Acid; Liver Cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE; GADOXETIC ACID; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BARCELONA CLINIC LIVER CANCER STAGE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER NODULE; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; AGED; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK FACTOR; SOUTH KOREA; TIME; TUMOR RECURRENCE; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GADOLINIUM DTPA; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84930038367     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.02.051     Document Type: Article

References (50)

1. R. Lozano, M. Naghavi, and K. Foreman Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
2. K.A. McGlynn, and W.T. London The global epidemiology of hepatocellular carcinoma: present and future Clin Liver Dis 15 2011 223 243
3. F. Kanwal, T. Hoang, and J.R. Kramer Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection Gastroenterology 140 2011 1182 1188
4. G.L. Davis, M.J. Alter, and H. El-Serag Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
5. J.D. Yang, and L.R. Roberts Epidemiology and management of hepatocellular carcinoma Infect Dis Clin North Am 24 2010 899 919
6. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 Suppl 1 2008 S20 S37
7. M.F. Yuen, C.C. Cheng, and I.J. Lauder Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience Hepatology 31 2000 330 335
8. N. Chalasani, A. Said, and R. Ness Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey Am J Gastroenterol 94 1999 2224 2229
9. H. Imamura, Y. Matsuyama, and E. Tanaka Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J Hepatol 38 2003 200 207
10. R.T. Poon, S.T. Fan, and I.O. Ng Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma Cancer 89 2000 500 507
11. Y.J. Chen, S.H. Yeh, and J.T. Chen Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma Gastroenterology 119 2000 431 440
12. J. Bruix, and M. Sherman American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
13. European Association for the Study of the Liver EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
14. A.B. Benson 3rd, T.A. Abrams, and E. Ben-Josef NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 2009 350 391
15. A. Colli, M. Fraquelli, and G. Casazza Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review Am J Gastroenterol 101 2006 513 523
16. T. Serste, V. Barrau, and V. Ozenne Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy Hepatology 55 2012 800 806
17. A. Forner, R. Vilana, and C. Ayuso Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104
18. K. Khalili, T.K. Kim, and H.J. Jang Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology 54 2011 2048 2054
19. K.I. Ringe, D.B. Husarik, and C.B. Sirlin Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver AJR Am J Roentgenol 195 2010 13 28
20. I. Cruite, M. Schroeder, and E.M. Merkle Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver AJR Am J Roentgenol 195 2010 29 41
21. B.E. Van Beers, C.M. Pastor, and H.K. Hussain Primovist, Eovist: what to expect? J Hepatol 57 2012 421 429
22. Y.K. Kim, C.S. Kim, and Y.M. Han Comparison of gadoxetic acid-enhanced MRI and superparamagnetic iron oxide-enhanced MRI for the detection of hepatocellular carcinoma Clin Radiol 65 2010 358 365
23. T.J. Vogl, S. Kummel, and R. Hammerstingl Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA Radiology 200 1996 59 67
24. Y.K. Kim, C.S. Kim, and Y.M. Han Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol 45 2010 740 746
25. R. Hammerstingl, A. Huppertz, and J. Breuer Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions Eur Radiol 18 2008 457 467
26. H. Akai, S. Kiryu, and I. Matsuda Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT Eur J Radiol 80 2011 310 315
27. Y.K. Kim, C.S. Kim, and Y.M. Han Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography J Comput Assist Tomogr 33 2009 844 850
28. M. Di Martino, D. Marin, and A. Guerrisi Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis Radiology 256 2010 806 816
29. T. Ichikawa, K. Saito, and N. Yoshioka Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease Invest Radiol 45 2010 133 141
30. T. Inoue, M. Kudo, and M. Komuta Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT J Gastroenterol 47 2012 1036 1047
31. Y.J. Jin, S.Y. Nah, and J.W. Lee Utility of adding Primovist magnetic resonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography Clin Gastroenterol Hepatol 11 2013 187 192
32. J. Fidler, and D. Hough Hepatocyte-specific magnetic resonance imaging contrast agents Hepatology 53 2011 678 682
33. M.J. Kim Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma Gut Liver 5 2010 15 21
34. X. Liu, L. Zou, and F. Liu Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis PLoS One 8 2013 e70896
35. S.E. Kim, H.C. Lee, and J.H. Shim Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area Liver Int 31 2011 1468 1476
36. T.K. Kim, K.H. Lee, and H.J. Jang Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma Radiology 259 2011 730 738
37. J.E. Kim, S.H. Kim, and S.J. Lee Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging AJR Am J Roentgenol 196 2011 W758 W765
38. M.J. Park, Y.K. Kim, and M.W. Lee Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns Radiology 264 2012 761 770
39. L.E. Braitman, and P.R. Rosenbaum Rare outcomes, common treatments: analytic strategies using propensity scores Ann Intern Med 137 2002 693 695
40. L.H. Curtis, B.G. Hammill, and E.L. Eisenstein Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases Med Care 45 2007 S103 S107
41. J.P. Klein, and M.L. Moeschberger Survival analysis: techniques for censored and truncated data 2003 Springer New York
42. M. Samuel, P.K. Chow, and E. Chan Shih-Yen Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma Cochrane Database Syst Rev 1 2009 CD001199
43. C.T. Chou, Y.L. Chen, and W.W. Su Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging J Magn Reson Imaging 32 2010 895 902
44. S.S. Ahn, M.J. Kim, and J.S. Lim Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 2010 459 466
45. S.H. Kim, S.H. Kim, and J. Lee Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma AJR Am J Roentgenol 192 2009 1675 1681
46. M. Sherman Hepatocellular carcinoma: screening and staging Clin Liver Dis 15 2011 323 334
47. J.M. Croswell, D.F. Ransohoff, and B.S. Kramer Principles of cancer screening: lessons from history and study design issues Semin Oncol 37 2010 202 215
48. W.C. Black Randomized clinical trials for cancer screening: rationale and design considerations for imaging tests J Clin Oncol 24 2006 3252 3260
49. A.R. Feinstein, D.M. Sosin, and C.K. Wells The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer N Engl J Med 312 1985 1604 1608
50. K. Sandrasegaran, B. Tahir, and K. Nutakki Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients AJR Am J Roentgenol 201 2013 1211 1219